-The Business Standard The recent US-India friction over trade is being driven by Big Pharma Apart from the deterioration of the business environment generally, which impacts both domestic and foreign investors, retrospective taxation has figured most prominently in the media as the principal cause of growing scepticism among foreign investors. Entirely missing from the discourse has been an equally potent factor with wholly foreign origins: the hijacking of the economic policy...

-Live Mint Mint examines why millions of women are missing from farms, factories, colleges, and offices in India, which has one of the lowest ratios of working women in the world Mumbai: Every monsoon, minivans ferrying women labourers can be seen making their way from the small sleepy town of Wardha to Waifad village, 18 kilometres away. Urban workers from Wardha have come to occupy an integral part of Waifad's farm...

-IPS News PESHAWAR, Pakistan- They are contraband, yet a large number of Pakistanis have come to depend on drugs made in India and smuggled into Pakistan. Patients as well as doctors say these are cheap and effective, even as law enforcers look the other way. The two countries do not have a trade agreement on drugs, but markets in Khyber Pakhtunkhwa province in the north of Pakistan do brisk business in India-made...

-The Indian Express India's role in pharmaceutical patent wars has broadened access to healthcare. Recently, there were rumours that the United States Trade Representative (USTR) was getting ready to announce "trade enforcement actions" or sanctions against India over its intellectual property rights regime. The Obama administration has been under pressure from the US Chamber of Commerce and lobby groups, like the Pharmaceutical Research and Manufacturers of America, to take a tough stance...

-The Hindu Chennai: With U.S Trade Representative Michael Froman set to announce a trade enforcement action tied to India, the highly influential U.S Chamber of Commerce has lashed out at India's recent pattern of Pharma patent denials, pointing out that the country's actions "are not about access to medicine." In the case of Swiss drug-maker Novartis, whose cancer drug's patent protections were dismissed by the Supreme Court, the chamber has argued that...